Retatrutide for Sleep Apnea: Does It Really Beat Tirzepatide?

Introduction

Obstructive sleep apnea (OSA) and obesity are deeply linked — excess fat around the neck and upper airway makes the airway more likely to collapse during sleep, causing the repeated breathing interruptions that define the condition. Because of that link, drugs that produce substantial weight loss have become a genuine treatment option for OSA, not just a side benefit of losing weight.

Retatrutide now has real data here. At the American Diabetes Association's 86th Scientific Sessions in June 2026, Eli Lilly presented results from a nested OSA substudy within TRIUMPH-1, showing a 60.6% reduction in the apnea-hypopnea index (AHI). Some early coverage has framed this as retatrutide outperforming tirzepatide — the only GLP-1-class drug with an existing FDA-approved OSA indication — on this measure. Checking that claim against Lilly's own published numbers for both drugs tells a more accurate story.

How OSA Is Being Studied in the Retatrutide Program

This is worth clarifying because it's a common point of confusion: there is no standalone "OSA trial" for retatrutide in the way TRIUMPH-4 is a standalone osteoarthritis trial. Instead, OSA is evaluated through nested basket substudies built into TRIUMPH-1 and TRIUMPH-2 — both of which are primarily weight management trials that include a defined cohort of participants with confirmed moderate-to-severe OSA (verified by polysomnography) alongside the main trial population.

The primary endpoint for these OSA baskets is change in AHI; key secondary endpoints include the percentage of participants achieving a ≥50% AHI reduction, patient-reported sleep impairment (PROMIS-SRI), and hypoxic burden (SASHB) — a measure that captures how much oxygen deprivation occurred during apnea events, which relates more directly to cardiovascular risk than AHI alone.

As of June 2026, only the TRIUMPH-1 OSA basket has reported results. TRIUMPH-2's OSA basket — nested within the obesity-with-diabetes population — hasn't reported yet, since TRIUMPH-2 overall is still ongoing.

The Results

A 60.6% AHI reduction is well above the 50% threshold generally considered clinically meaningful for sleep apnea treatment, and it moved the average participant from the severe OSA category at baseline into the moderate range. It does not, on its own, mean most participants no longer have OSA — moving from 58.6 to roughly 22.5 events per hour is a major improvement, but 22.5 still exceeds the American Academy of Sleep Medicine's clinical significance threshold of 15 events per hour for many patients.

How This Compares to Tirzepatide (Zepbound)

Tirzepatide is the only GLP-1-class drug with large-scale, published OSA trial data to date, from the SURMOUNT-OSA program — two Phase 3 trials (one in patients not using PAP therapy, one in patients continuing PAP therapy), published in The New England Journal of Medicine in 2024.

Note: these come from separate trials with different designs — tirzepatide's SURMOUNT-OSA ran two parallel studies (with and without PAP therapy) over 52 weeks, while retatrutide's TRIUMPH-1 OSA basket ran 80 weeks. Longer trial duration can itself produce larger improvements in this drug class, so the comparison isn't fully apples-to-apples — but both percentages are official, company-disclosed headline figures.

The honest read here: tirzepatide's headline figure is modestly higher, not lower — and it got there in a shorter trial duration. Some secondary coverage of retatrutide's OSA data has claimed it's "numerically superior" to tirzepatide — that claim doesn't hold up against Lilly's own tirzepatide press release, which cites "up to 62.8%" for SURMOUNT-OSA. Both results are genuinely strong; if anything, tirzepatide's is the more impressive one given it was achieved in roughly two-thirds of the trial time.

Tirzepatide also has something retatrutide doesn't yet: an FDA-approved indication specifically for OSA (since December 2024), making it the first GLP-1-class drug authorized for this use. Retatrutide's OSA benefit remains investigational until the full TRIUMPH program completes and the FDA reviews it as part of a broader submission.

For a full head-to-head on weight loss and other measures, see our vs Tirzepatide vs Semaglutide comparison.

Why Weight Loss Improves Sleep Apnea

The connection isn't unique to retatrutide's mechanism — it's a general property of effective weight loss. Excess fat deposited around the neck, tongue, and soft palate narrows the upper airway and makes it more prone to collapsing during sleep, particularly when muscle tone relaxes in deeper sleep stages. Reducing that fat deposit, through any sufficiently effective method, tends to reduce how often and how severely the airway collapses.

This means the OSA improvement seen with retatrutide is best understood as a downstream effect of its substantial weight loss (28.3% in the broader TRIUMPH-1 population) rather than evidence that its triple-hormone mechanism does something uniquely beneficial for the airway beyond what equivalent weight loss from another drug would produce. That also helps explain the tirzepatide comparison: tirzepatide produces somewhat less average weight loss than retatrutide overall, yet matched or slightly exceeded it on AHI reduction in its own OSA-specific trial — a reminder that the relationship between total weight loss and AHI improvement isn't perfectly linear, and trial-specific factors (population, duration, measurement timing) matter too.

What This Means If You Have OSA and Obesity

If retatrutide is eventually approved with data supporting an OSA-related benefit, it would join tirzepatide as a pharmacological alternative — or complement — to CPAP/PAP therapy for appropriately selected patients. It's worth being clear that this isn't a CPAP replacement recommendation; the SURMOUNT-OSA data showed benefit in patients both using and not using PAP, and any future retatrutide guidance would need similar physician-directed evaluation based on individual disease severity and cardiovascular risk.

For the complete picture of where retatrutide's broader Phase 3 program stands, see our complete retatrutide guide.

Conclusion

Retatrutide's TRIUMPH-1 OSA substudy delivered a real, clinically meaningful result: a 60.6% reduction in AHI over 80 weeks, moving the average participant from severe to moderate sleep apnea. But contrary to some early coverage, it doesn't establish retatrutide as superior to tirzepatide on this measure — tirzepatide's own published SURMOUNT-OSA data shows a slightly higher headline reduction (62.8%), achieved in a shorter 52-week trial. The improvement in both cases is best understood as a product of substantial weight loss rather than a distinct airway-specific mechanism, which is consistent with how weight loss generally improves OSA across this drug class.

TRIUMPH-2's OSA basket, in a population with both obesity and type 2 diabetes, hasn't reported yet and will add to this picture. Until retatrutide's full data package is reviewed by the FDA, tirzepatide remains the only GLP-1-class option with an approved indication specifically for sleep apnea.

Sources

• Eli Lilly and Company. "Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea." PRNewswire, June 6, 2026.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Eli Lilly and Company. "Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity." PRNewswire, April 17, 2024.
• Eli Lilly and Company. "Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution." PRNewswire, June 21, 2024.
• Malhotra A, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." New England Journal of Medicine, 2024.